We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Synaptogenix Inc (SNPX) USD0.0001

Sell:$3.01 Buy:$4.00 Change: $0.19 (5.66%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$3.01
Buy:$4.00
Change: $0.19 (5.66%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Sell:$3.01
Buy:$4.00
Change: $0.19 (5.66%)
Market closed |  Prices as at close on 14 January 2025 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Synaptogenix, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative disorders. The Company is principally focused on developing a product platform based upon a drug candidate called Bryostatin-1, which is synthesized from a natural product (bryostatin) that is isolated from a marine invertebrate organism, for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. It has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in AD.

Contact details

Address:
1185 AVENUE OF THE AMERICAS, 3RD FLOOR
NEW YORK
10036
United States
Telephone:
+1 (973) 2420005
Website:
https://www.synaptogen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SNPX
ISIN:
US87167T3005
Market cap:
$4.53 million
Shares in issue:
1.36 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Daniel Alkon
    President, Chief Scientific Officer, Director
  • Alan Tuchman
    Chief Executive Officer, Director
  • Robert Weinstein
    Chief Financial Officer, Executive Vice President, Treasurer, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.